BRIEFING

 〈1301〉 Pharmacogenomics—Glossary Of Terms. The Personalized Medicines Expert Committee (PMEC) is proposing the following new general information chapter. As USP initiates standards development in pharmacogenomics (PGx), consistent use and understanding of terminology is essential to support the development, interpretation, and future application of PGx standards across the healthcare ecosystem. This glossary provides concise definitions of PGx-relevant terms and resources, and is intended to:

• Establish a shared, baseline vocabulary for pharmacogenomics to enable consistent interpretation of PGx concepts across stakeholders.

• Lay a foundation for future USP PGx standards, supporting clear communication as standards expand into areas such as nomenclature, laboratory practices, and downstream use in health records and clinical decision-making.

• Promote clarity and consistency by providing definitions that are concise and, where feasible, aligned with established scientific, clinical, and regulatory usage—while reflecting how terms are applied in the USP pharmacogenomics context.

 This glossary is designed for stakeholders who will use or engage with USP’s PGx standards work, including clinicians, laboratories, regulators, payers, and technical organizations. It is not intended as a beginner educational resource; it assumes readers have baseline clinical and/or genomics literacy and focuses on conceptual meaning rather than operational detail.

 (PM: V. Cancelliere)

 Case ID—SUB-3289